• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: 80% of pharma outsource some of their government reimbursement budgets

Report: 80% of pharma outsource some of their government reimbursement budgets

November 24, 2014
CenterWatch Staff

Eighty percent of surveyed pharma companies outsource some portion of their government reimbursement budgets, including third-party audits that can help companies remain compliant to changing industry guidelines, according to Cutting Edge Information, a Research Triangle Park, N.C.-based pharmaceutical business intelligence provider.

In the survey, advisors indicated that many companies either are unaware of or ignore government pricing and other trade policy guidelines set forth by the Office of Inspector General (OIG), which often are priority areas for government agencies. 

"The Affordable Care Act has served as a catalyst for change in the pharmaceutical industry. The new guidelines, however, can be confusing and it is therefore imperative that companies take appropriate steps to ensure that they are government compliant," said Jacob Presson, senior research analyst at Cutting Edge Information. "An OIG compliance audit from a third-party advisor can mitigate the risk of trouble with the U.S. Department of Justice."

Presson said, “Companies outsource up to a quarter of their government reimbursement budgets on a variety of activities, including customer relationship management, price model-building and auditing. The type of outsourced activity will vary depending on the size and needs of a company, but according to one interviewed executive, third-party vendors "touch the entire food chain from reps to CEO." 

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing